Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 6.33
-0.03 (-0.47%)
Apr 2, 2026, 4:08 PM HKT
Sino Biopharmaceutical Employees
Sino Biopharmaceutical had 21,435 employees as of December 31, 2025. The number of employees decreased by 2,944 or -12.08% compared to the previous year.
Employees
21,435
Change
-2,944
Growth
-12.08%
Revenue / Employee
1.65M HKD
Profits / Employee
121.66K HKD
Market Cap
113.10B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21,435 | -2,944 | -12.08% |
| Jun 30, 2025 | 23,056 | - | - |
| Dec 31, 2024 | 24,379 | -1,427 | -5.53% |
| Dec 31, 2023 | 25,806 | -466 | -1.77% |
| Dec 31, 2022 | 26,272 | 693 | 2.71% |
| Dec 31, 2021 | 25,579 | 1,471 | 6.10% |
| Mar 31, 2021 | 24,262 | 960 | 4.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| WuXi Biologics | 13,252 |
| BeOne Medicines AG | 12,000 |
| Innovent Biologics | 7,502 |
| 3SBio | 6,268 |
| Shanghai Henlius Biotech | 3,762 |
| Akeso | 3,761 |
| RemeGen | 3,048 |
| Shanghai Junshi Biosciences | 2,903 |
Sino Biopharmaceutical News
- 4 weeks ago - Sino Biopharmaceutical (SBHMY) Strikes $1.53B Deal with Sanofi for Cancer Drug - GuruFocus
- 4 weeks ago - China outlicensing tops US$52 billion in first 2 months on rise in global deals - South China Morning Post
- 4 weeks ago - Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln - Reuters
- 2 years ago - Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln - Reuters
- 5 years ago - Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea - Forbes